dBET1 CAS 1799711-21-9

Introduction：Basic information about dBET1 CAS 1799711-21-9, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

dBET1 Basic information

• Product Name: dBET1
• Synonyms: dBET1;DBET1;DBET-1 ;DBET 1;CS-2706;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-, (6S)-;N-(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,2,6]trideca-2 (6),4,7,10,12-pentaen-9-yl]acetamido}butyl)-2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-i soindol-4-yl]oxy}acetamide;2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)acetamide;dBET1,inhibit,PROTACs,Epigenetic Reader Domain,Inhibitor,dBET 1,dBET-1;JQ1-Thalidomide conjugate
• CAS: 1799711-21-9
• MF: C38H37ClN8O7S
• MW: 785.27
• Mol File: 1799711-21-9.mol

dBET1 Chemical Properties

• Melting point: 186 - 187°C
• density: 1.55±0.1 g/cm3(Predicted)
• storage temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• solubility: DMSO (Slightly), Methanol (Slightly)
• pka: 10.68±0.40(Predicted)
• form: Solid
• color: Pale Yellow
• Stability: Hygroscopic
• InChIKey: LKEGXJXRNBALBV-PMCHYTPCSA-N
• SMILES: N12C(C)=NN=C1[C@H](CC(NCCCCNC(COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)=O)=O)N=C(C1=CC=C(Cl)C=C1)C1C(C)=C(C)SC=12

Safety Information

• HS Code: 2933998090

dBET1 Usage And Synthesis

Description

dBET1 is a PROTAC compound comprised of BET bromodomain antagonist (+)-JQ1 linked to a cereblon E3 ubiquitin ligase ligand.

Uses

dBET1 induces highly selective cereblon-dependent BET protein degradation in vitro and in vivo as well as delays leukemia progression in mice.

in vivo

Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count^[1].

IC 50

BRD4: 430 nM (EC₅₀); Cereblon

storage

Store at -20°C